510 related articles for article (PubMed ID: 25704616)
41. Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat.
Hao JX; Wiesenfeld-Hallin Z; Xu XJ
Neurosci Lett; 1997 Feb; 223(1):49-52. PubMed ID: 9058420
[TBL] [Abstract][Full Text] [Related]
42. Activation of opioid receptor like-1 receptor in the spinal cord produces sex-specific antinociception in the rat: estrogen attenuates antinociception in the female, whereas testosterone is required for the expression of antinociception in the male.
Claiborne J; Nag S; Mokha SS
J Neurosci; 2006 Dec; 26(50):13048-53. PubMed ID: 17167094
[TBL] [Abstract][Full Text] [Related]
43. Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test.
Rizzi A; Ruzza C; Bianco S; Trapella C; Calo' G
Peptides; 2017 Aug; 94():71-77. PubMed ID: 28697954
[TBL] [Abstract][Full Text] [Related]
44. Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies.
Ko MC; Wei H; Woods JH; Kennedy RT
J Pharmacol Exp Ther; 2006 Sep; 318(3):1257-64. PubMed ID: 16766718
[TBL] [Abstract][Full Text] [Related]
45. The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.
Brookes ZL; Stedman EN; Brown NJ; Hebbes CP; Guerrini R; Calo G; Reilly CS; Lambert DG
PLoS One; 2013; 8(9):e74943. PubMed ID: 24086402
[TBL] [Abstract][Full Text] [Related]
46. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
Zaveri NT
Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
[TBL] [Abstract][Full Text] [Related]
47. Evidence for an exclusive antinociceptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain.
Courteix C; Coudoré-Civiale MA; Privat AM; Pélissier T; Eschalier A; Fialip J
Pain; 2004 Jul; 110(1-2):236-45. PubMed ID: 15275773
[TBL] [Abstract][Full Text] [Related]
48. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat.
Tian JH; Xu W; Fang Y; Mogil JS; Grisel JE; Grandy DK; Han JS
Br J Pharmacol; 1997 Feb; 120(4):676-80. PubMed ID: 9051307
[TBL] [Abstract][Full Text] [Related]
49. Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats.
Economidou D; Fedeli A; Fardon RM; Weiss F; Massi M; Ciccocioppo R
Peptides; 2006 Dec; 27(12):3299-306. PubMed ID: 17097763
[TBL] [Abstract][Full Text] [Related]
50. Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats.
Agostini S; Eutamene H; Broccardo M; Improta G; Petrella C; Theodorou V; Bueno L
Pain; 2009 Feb; 141(3):292-299. PubMed ID: 19147291
[TBL] [Abstract][Full Text] [Related]
51. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
J Pept Res; 2004 Jun; 63(6):477-84. PubMed ID: 15175020
[TBL] [Abstract][Full Text] [Related]
52. Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor.
Depner UB; Reinscheid RK; Takeshima H; Brune K; Zeilhofer HU
Eur J Neurosci; 2003 Jun; 17(11):2381-7. PubMed ID: 12814369
[TBL] [Abstract][Full Text] [Related]
53. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
Gündüz O; Rizzi A; Baldisserotto A; Guerrini R; Spagnolo B; Gavioli EC; Kocsis L; Magyar A; Benyhe S; Borsodi A; Calò G
Eur J Pharmacol; 2006 Jun; 539(1-2):39-48. PubMed ID: 16682024
[TBL] [Abstract][Full Text] [Related]
54. Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon.
Grandi D; Massi M; Guerrini R; Caló G; Morini G
Life Sci; 2011 Nov; 89(19-20):735-40. PubMed ID: 21925513
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.
Viaro R; Calcagno M; Marti M; Borrelli E; Morari M
Neuropharmacology; 2013 Sep; 72():126-38. PubMed ID: 23643745
[TBL] [Abstract][Full Text] [Related]
56. Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats.
Delaney G; Dawe KL; Hogan R; Hunjan T; Roper J; Hazell G; Lolait SJ; Fulford AJ
J Neuroendocrinol; 2012 Dec; 24(12):1527-41. PubMed ID: 22835008
[TBL] [Abstract][Full Text] [Related]
57. Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.
Peng YL; Chang M; Dong SL; Li W; Han RW; Fu GX; Chen Q; Wang R
Regul Pept; 2006 May; 134(2-3):75-81. PubMed ID: 16516988
[TBL] [Abstract][Full Text] [Related]
58. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
[TBL] [Abstract][Full Text] [Related]
59. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
[TBL] [Abstract][Full Text] [Related]
60. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
